Sparsentan

司帕生坦

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameSparsentan
Drug Alias NameSparsentanumDARAFilspariBMS-346567RE-021 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsEndothelin receptor type A antagonists
TargetsEndothelin receptor type AAngiotensin II Receptor Type 1
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[13] 
Global Approved IndicationsGlomerulonephritis, IGA
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/02/17
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalRenalys Pharma IncChugai Pharmaceutical Co Ltd +[8] 
Inactive CompaniesLigand Pharmaceuticals Inc
Active IndicationsAutoimmune DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPurpura, Schoenlein-Henoch +[10] 
Inactive IndicationsImmune System DiseasesHypertensionCardiovascular Diseases

Other Information

ATC CodeC09XX01
Related LinksDrugBankKEGG